UMIN000049194Recruitment Completed
Multicenter retrospective study evaluating the efficacy and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer.
North East Japan Study GroupUniversity Hospital Medical Information Network
VerifiedUniversity Hospital Medical Information Network
Study focus
- Disease/Condition
- Non-small cell lung cancer
- Study type
- Observational
Sponsor & location
- Primary sponsor
- North East Japan Study Group
- Location
- Japan
Timeline & enrollment
- Phase
- N/A
- Start date
- Oct 12, 2022
- End date
- N/A
ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
- Registry
- University Hospital Medical Information Network
- Trial ID
- UMIN000049194
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for UMIN000049194 through Pure Global AI's free database. This phase not specified trial is sponsored by North East Japan Study Group and is currently Recruitment Completed. The study focuses on Non-small cell lung cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to University Hospital Medical Information Network data, helping medical device and pharmaceutical companies navigate clinical research efficiently.